Impact News +++ Magnum Ice Cream Co serves up mixed first final results after demerger (Proactive Investors) +++ MAGNUM ICE CREAM Aktie -9,62%

NEUROCRINE Aktie

>NEUROCRINE Aktienkurs

111.05 EUR -4.1% (TradegateBSX)

Ask: 112.3 EUR / 45 Stück

Bid: 111.05 EUR / 46 Stück

Tagesumsatz: 107 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

NEUROCRINE Aktie über LYNX handeln

Intraday

1 Jahr

>NEUROCRINE Performance

1 Woche: -2,5%

1 Monat: +0,1%

3 Monate: -7,8%

6 Monate: +7,7%

1 Jahr: +3,9%

laufendes Jahr: -4,1%

>NEUROCRINE Aktie

Name:

NEUROCRINE BIOSCI. DL-001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US64125C1099 / 900964

Symbol/ Ticker:

NB3 (Frankfurt) / NBIX (NASDAQ)

Kürzel:

FRA:NB3, ETR:NB3, NB3:GR, NASDAQ:NBIX

Index:

Webseite:

http://www.neurocrine.com..

Profil:

Neurocrine Biosciences Inc. is a biopharmaceutical..
>Volltext..

Marktkapitalisierung:

11693.76 Mio. EUR

Unternehmenswert:

11151.88 Mio. EUR

Umsatz:

2254.47 Mio. EUR

EBITDA:

490.19 Mio. EUR

Nettogewinn:

359.68 Mio. EUR

Gewinn je Aktie:

3.62 EUR

Schulden:

403.13 Mio. EUR

Liquide Mittel:

285.9 Mio. EUR

Operativer Cashflow:

535.15 Mio. EUR

Bargeldquote:

1.75

Umsatzwachstum:

13.49%

Gewinnwachstum:

5.24%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 4.830.458 USD.

Suchwörter:

NEUROCRINE

Letzte Datenerhebung:

12.02.26

>NEUROCRINE Kennzahlen

Aktien/ Unternehmen:

Aktien: 99.71 Mio. St.

Frei handelbar: 97.33%

Leerverk. Aktien: 3.35%

Rückkaufquote: 2.63%

Mitarbeiter: 1800

Umsatz/Mitarb.: 1.1 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 31.56%

Bewertung:

KGV: 32.45

KGV lG: 26.61

KUV: 5.08

KBV: 4.51

PEG-Ratio: 2.61

EV/EBITDA: 22.75

Rentabilität:

Bruttomarge: 98.14%

Gewinnmarge: 15.95%

Operative Marge: 20.64%

Managementeffizenz:

Gesamtkaprendite: 10.97%

Eigenkaprendite: 14.96%

>NEUROCRINE Peer Group

Gesundheit

>NEUROCRINE Chart & Kurs - NASDAQ

>NEUROCRINE News

12.02.26 - 03:12	Neurocrine (NBIX) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 02:18	Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 01:00	Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
	While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

12.02.26 - 01:00	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
	Neurocrine (NBIX) delivered earnings and revenue surprises of -16.55% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.02.26 - 00:01	Neurocrine übertrifft Prognosen für Q4 2025 – Aktie legt zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 22:30	Neurocrine Biosciences Inc Profit Advances In Q4 (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) announced earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $153.7 million, or $1.48 per shar......

11.02.26 - 22:09	Neurocrine Biosciences Non-GAAP EPS of $1.88 misses by $0.42, revenue of $805.5M beats by $16.2M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 22:03	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
	Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ --......

06.02.26 - 16:45	Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
	Get a deeper insight into the potential performance of Neurocrine (NBIX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics....

04.02.26 - 17:30	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
	Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

26.01.26 - 14:33	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
	SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the......

23.01.26 - 21:12	What Analysts Are Saying About Neurocrine Biosciences Stock (Benzinga)
	Latest Ratings for NBIX DateFirmActionFromTo Mar 2022Piper SandlerDowngradesOverweightNeutral Feb 2022Goldman SachsUpgradesNeutralBuy Feb 2022Morgan StanleyMaintainsEqual-Weight View More Analyst Ratings for NBIX View the Latest Analyst Ratings read more...

22.01.26 - 19:45	Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? (Zacks)
	Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

21.01.26 - 22:03	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results (PR Newswire)
	Conference Call and Webcast Scheduled for Wednesday, February 11 SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m.......

21.01.26 - 15:48

Immedica completes acquisition of Neurocrine Group Limited, Neurocrine Biosciences′ European rare commercial business (Cision)

Portfolio includes global rights to Alkindi® (hydrocortisone) and global rights ex-US to Efmody® (hydrocortisone modified-release) Stockholm, Sweden – January 21, 2026 – Immedica Pharma AB today announced that it has completed the acquisition of Neurocrine Group Limited and subsidiaries (NGL; formerly known as Diurnal Group) from Neurocrine Biosciences. The acquisition includes the global rights to Alkindi® (hydrocortisone oral granules) and the assets and global rights excluding the United States of America to Efmody® (hydrocortisone modified-release hard capsules). The products...

21.01.26 - 07:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Neurocrine Biosciences im Wert von 4830458 USD (Insiderkauf)
	Gano, Kyle - Vorstand - Tag der Transaktion: 2026-01-16...

15.01.26 - 14:33	Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR (PR Newswire)
	INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatment VMAT2 occupancy is a key measurement thought to be associated with drug response in involuntary movement......

08.01.26 - 18:00

Immedica to acquire Neurocrine Group Limited, Neurocrine Biosciences′ European rare commercial business (Cision)

Portfolio includes global rights to Alkindi® (hydrocortisone) and global rights ex-US to Efmody® (hydrocortisone modified-release) Stockholm, Sweden – January 8, 2026 - Immedica Pharma AB today announced that it has entered into a definitive agreement to acquire Neurocrine Group Limited and subsidiaries (NGL; formerly known as Diurnal Group), including the assets and global rights to Alkindi® (hydrocortisone oral granules) and the assets and global rights (excluding the United States of America) to Efmody® (hydrocortisone modified-release hard capsules), from Neurocrine Biosciences. The $65...

05.01.26 - 22:03	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
	SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.......

23.12.25 - 05:12	Neurocrine: Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced that its Phase 3 KINECT-DCP study evaluating valbenazine in pediatric and adult participants with dyskinetic cerebral palsy (DCP......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Mag alles Leid und Schatten sein - doch diese süße Sonnenstunde nicht, und nicht der Duft vom roten Klee, und nicht das tiefe, zarte Wohlgefühl in meiner Seele. - Hermann Hesse

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram